486 related articles for article (PubMed ID: 29228826)
1. Synthesis, physicochemical properties and ocular pharmacokinetics of thermosensitive in situ hydrogels for ganciclovir in cytomegalovirus retinitis treatment.
Wang Q; Sun C; Xu B; Tu J; Shen Y
Drug Deliv; 2018 Nov; 25(1):59-69. PubMed ID: 29228826
[TBL] [Abstract][Full Text] [Related]
2. Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis.
Duvvuri S; Janoria KG; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2007 Jun; 23(3):264-74. PubMed ID: 17593010
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, characterization, biodegradability and biocompatibility of a temperature-sensitive PBLA-PEG-PBLA hydrogel as protein delivery system with low critical gelation concentration.
Xu Y; Shen Y; Xiong Y; Li C; Sun C; Ouahab A; Tu J
Drug Dev Ind Pharm; 2014 Sep; 40(9):1264-75. PubMed ID: 23855735
[TBL] [Abstract][Full Text] [Related]
4. An injectable thermosensitive polymeric hydrogel for sustained release of Avastin® to treat posterior segment disease.
Xie B; Jin L; Luo Z; Yu J; Shi S; Zhang Z; Shen M; Chen H; Li X; Song Z
Int J Pharm; 2015 Jul; 490(1-2):375-83. PubMed ID: 26027491
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir.
Cheng L; Hostetler KY; Lee J; Koh HJ; Beadle JR; Bessho K; Toyoguchi M; Aldern K; Bovet JM; Freeman WR
Invest Ophthalmol Vis Sci; 2004 Nov; 45(11):4138-44. PubMed ID: 15505067
[TBL] [Abstract][Full Text] [Related]
6. Thermosensitive PEG-PCL-PEG (PECE) hydrogel as an in situ gelling system for ocular drug delivery of diclofenac sodium.
Luo Z; Jin L; Xu L; Zhang ZL; Yu J; Shi S; Li X; Chen H
Drug Deliv; 2016; 23(1):63-8. PubMed ID: 24758189
[TBL] [Abstract][Full Text] [Related]
7. Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis.
Sakurai E; Matsuda Y; Ozeki H; Kunou N; Nakajima K; Ogura Y
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2043-8. PubMed ID: 11481270
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle-based topical ophthalmic formulation for sustained release of stereoisomeric dipeptide prodrugs of ganciclovir.
Yang X; Shah SJ; Wang Z; Agrahari V; Pal D; Mitra AK
Drug Deliv; 2016 Sep; 23(7):2399-2409. PubMed ID: 25564964
[TBL] [Abstract][Full Text] [Related]
9. Formulation development and in vitro evaluation of transferrin-conjugated liposomes as a carrier of ganciclovir targeting the retina.
Asasutjarit R; Managit C; Phanaksri T; Treesuppharat W; Fuongfuchat A
Int J Pharm; 2020 Mar; 577():119084. PubMed ID: 31988033
[TBL] [Abstract][Full Text] [Related]
10. [Ocular pharmacokinetics and bioavailability of 0.2% ganciclovir in-situ gelling eye drops].
Zhang JJ; Gao CF; Wang LY
Zhonghua Yan Ke Za Zhi; 2006 Jul; 42(7):637-41. PubMed ID: 17081425
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation.
Cheng L; Hostetler KY; Chaidhawangul S; Gardner MF; Beadle JR; Keefe KS; Bergeron-Lynn G; Severson GM; Soules KA; Mueller AJ; Freeman WR
Invest Ophthalmol Vis Sci; 2000 May; 41(6):1523-32. PubMed ID: 10798672
[TBL] [Abstract][Full Text] [Related]
12. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis.
Kunou N; Ogura Y; Yasukawa T; Kimura H; Miyamoto H; Honda Y; Ikada Y
J Control Release; 2000 Aug; 68(2):263-71. PubMed ID: 10925134
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel formulation containing poly(d,l-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir.
Duvvuri S; Janoria KG; Mitra AK
J Control Release; 2005 Nov; 108(2-3):282-93. PubMed ID: 16229919
[TBL] [Abstract][Full Text] [Related]
14. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy.
Kajiwara E; Kawano K; Hattori Y; Fukushima M; Hayashi K; Maitani Y
J Control Release; 2007 Jul; 120(1-2):104-10. PubMed ID: 17509714
[TBL] [Abstract][Full Text] [Related]
15. Preparation and ocular pharmacokinetics of ganciclovir liposomes.
Shen Y; Tu J
AAPS J; 2007 Dec; 9(3):E371-7. PubMed ID: 18170984
[TBL] [Abstract][Full Text] [Related]
16. Sustained-release hydrogels of topotecan for retinoblastoma.
Taich P; Moretton MA; Del Sole MJ; Winter U; Bernabeu E; Croxatto JO; Oppezzo J; Williams G; Chantada GL; Chiappetta DA; Schaiquevich P
Colloids Surf B Biointerfaces; 2016 Oct; 146():624-31. PubMed ID: 27429296
[TBL] [Abstract][Full Text] [Related]
17. Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Eperimental toxicity and pharmacokinetics, and clinical trial.
Díaz-Llopis M; Martos MJ; España E; Cervera M; Vila AO; Navea A; Molina FJ; Romero FJ
Doc Ophthalmol; 1992; 82(4):297-305. PubMed ID: 1339115
[TBL] [Abstract][Full Text] [Related]
18. Sustained release of intravitreal flurbiprofen from a novel drug-in-liposome-in-hydrogel formulation.
Pachis K; Blazaki S; Tzatzarakis M; Klepetsanis P; Naoumidi E; Tsilimbaris M; Antimisiaris SG
Eur J Pharm Sci; 2017 Nov; 109():324-333. PubMed ID: 28843864
[TBL] [Abstract][Full Text] [Related]
19. Ganciclovir delivery through an intravitreal microdialysis probe in rabbit.
Waga J
Acta Ophthalmol Scand; 2000 Jun; 78(3):369-71. PubMed ID: 10893076
[TBL] [Abstract][Full Text] [Related]
20. In situ gelling polyvalerolactone-based thermosensitive hydrogel for sustained drug delivery.
Mishra GP; Kinser R; Wierzbicki IH; Alany RG; Alani AW
Eur J Pharm Biopharm; 2014 Oct; 88(2):397-405. PubMed ID: 24931340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]